(incorporating eIMA News)
16th March 2016
Editorial (Dr SS Agarwal, Dr K K Aggarwal)
Fixed drug combinations banned: Matter in court
The Delhi High Court has granted US pharmaceuticals giant Pfizer Inc's India unit a stay on a government ban on its popular cough syrup Corex (chlorpheniramine maleate and codeine).
The ban on Pfizer's cough syrup was part of a wider notice issued by the government ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans. March 21 is the date for the next hearing by the Delhi High Court on Pfizer's plea.
The court said the government had not issued Pfizer a "show cause notice" before banning the medicine.
The ban also applied to Abbott Laboratories' Phensedyl cough syrup and Abbott's Indian subsidiary also filed a writ petition at the same court, which will come up for hearing on Tuesday. A panel of experts found the drugs lacked "therapeutic justification".
The sale of fixed dose combination medicines in India requires the approval of the central government. But several drug combinations have entered the market over the years based solely on approval from individual states.
In 2007 it ordered states to recall about 300 such combination drugs, but drug makers challenged it in court and the order was stayed.
In 2014, India set up a panel of experts to review over 6,000 such drug combinations, and asked companies to submit data to prove safety and efficacy of their drugs. 344 of those have been banned.

Standard Notification for all drugs.
Notification New Delhi, the 10th March, 2016 S.O. 983(E).—
Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Codeine Phosphate + Menthol Syrup is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
To Read More or Comment, Click Here
Top News
Practice Updates
Lighter Reading
Medicolegal Corner
eMedi Quiz
A. Agree with and encourage the client’s denial
B. Reassure the client that everything will be okay 
C. Allow the denial but be available to discuss death 
D. Leave the client alone to discuss the loss
Photo Quiz
Webcast & Video of the Day
Lifestyle Updates
eWellness: All about tea
When we speak of tea, it is commonly assumed to be black tea with milk and sugar. However, the word ‘Tea’ means any herb. This means even hot Tulsi water...Read more

eSpiritual: What are the Ethics of Vidur Niti?

The best description of the causes and treatment of insomnia comes from Vidura Niti, a dialogue between Vidura and Dhritarashtra...Read more

Inspirational Story: Life and Love’s Unending Journey
Love should always remain hopeful and positive in the difficult journey that follows along lives "bumpy detours and highways". Love should never lead dreamers astray, left to...Read more
Questions Answered By KOL's
Second Opinion Required
Dr Shilpa Saxena - what is treatment of infertility in case of absent vas deferense with normal spermatogenesis . iui must be trialed or can switch over directly to ivf. what r succes rates of iui and ivf?

Press Release
Heart Care Foundation of India comes to the aid of heart disease patients who cannot otherwise afford treatment 
  • The Sameer Malik Heart Care Foundation Fund has helped save the lives of many men, women and children who had lost all hope due to their financial status
  • While any person can apply for the benefits of the fund by calling +919958771177, girl children get first preference 
New Delhi, March 15, 2016: Mrs. Geeta Devi, age 52, a vegetable seller from Haryana was the sole bread earner for her family. She was diagnosed with severe blockages in her heart when she complained of chest discomfort and breathlessness. She was advised a bypass surgery. A mother of six children, Geeta Devi, did not have the money to pay for her surgery and gave up all hope. When she found out about the Sameer Malik Heart Care Foundation Fund, her hope for a healthy and long life was restored. 

When she approached Heart Care Foundation of India's office and was advised an immediate bypass surgery by its President and Cardiologist, Dr. KK Aggarwal she was apprehensive. She was scared that if something happened to her, how her family would feed themselves. However, she took the leap of faith and agreed to the surgery at National Heart Institute. She was successfully operated upon and now is leading a healthy life.

An initiative by leading National NGO, Heart Care Foundation of India, the Sameer Malik Heart Care Foundation Fund (SMHCFF), is based on the principle that no person should die of heart disease just because they cannot afford treatment. Since its inception, the fund provided technical and financial support to almost 400 patients, majority of which are women. 
To Read More or Comment, Click Here
IMA Updates
IMA Polio Dates
  • April 1st: tOPV would not be available after this date.
  • April 11th: bOPV would be available in private market but it is not to be opened or used before 25th April.
  • April 25: IMA Polio Switch Day, when tOPV would be completely withdrawn and replaced by bOPV in both routine immunization and polio campaigns.
  • 9th May: IMA National Validation Day when India would be declared free of tOPV. 

IMA Satyagraha - https://www.youtube.com/watch?v=UV1zCH33BlU

Dr Good Dr Bad And Make Sure
eIMA News Update
Digital IMA
The Indian Medical Association (IMA) presents a series of weekly webcasts for the benefit of the Indian medical profession, engaging you with the latest in advocacy efforts for doctors, through an interactive exclusive digital webcast partnership with eMediNexus.

Next Webcast: 17th
 March 2016